Partnerships and Engagements

BOSTON, OpenEye miniCUP—Sept. 25, 2025—Cadence Molecular Sciences (OpenEye), a business unit of Cadence (Nasdaq: CDNS), announced today at miniCUP Boston, the launch of ROCS X, an AI-enabled virtual screening solution that allows scientists to conduct 3D searches of trillions of drug-like molecules.

Webinar: OpenEye's Free energy prediction for drug discovery: Ideas at breakfast, discoveries by lunch We are continuing our 2025 miniWEBINAR series with our November session led by Chris Neale, Ph.D., who leads the molecular binding affinity solution group at OpenEye, Cadence Molecular Sciences. His expertise and interests include method development for structure-based drug design, cellular signal transduction, and uncertainty quantification. Chris is also an editorial board member at the Biophysical Journal.